Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]

Core Insights - The TNF-α inhibitor market is experiencing rapid growth due to the increasing prevalence of autoimmune diseases and the urgent treatment needs of a large patient population [1][5][12] - In China, the market penetration rate of TNF-α inhibitors was only 0.31% in 2018, compared to 13.36% in the U.S., indicating significant growth potential for the industry [1][5] - The market size for TNF-α inhibitors in China is projected to reach 16.3 billion yuan in 2024, representing a year-on-year increase of 25.4% [1][5] TNF-α Inhibitor Industry Overview - TNF-α inhibitors are targeted biological agents that reduce inflammation and immune activation, primarily used for various autoimmune diseases [4][5] - The development of TNF-α inhibitors began in the 1990s, with the first drug, Infliximab, approved in 1998, marking the start of a new era in treating autoimmune diseases [4][5] Current Market Status - The TNF-α inhibitor market is expanding rapidly, attracting numerous domestic pharmaceutical companies, which has led to increased market penetration and growth [1][5] - The leading TNF-α inhibitors in the market include Adalimumab, Etanercept, and Infliximab, with Adalimumab holding a market share of 48.83% [6][7] Competitive Landscape - The TNF-α inhibitor industry is characterized by a dominance of foreign pharmaceutical companies, with local companies like Innovent Biologics and Junshi Biosciences rapidly gaining market share [7][9] - The competition is intensifying as more companies enter the market, leading to price reductions and increased pressure on profit margins [12] Future Trends - Future developments in the TNF-α inhibitor market will focus on improving therapeutic efficacy and reducing side effects through structural modifications and personalized treatment approaches [10][11] - The industry is expected to see increased competition, with many companies entering the market, leading to potential market consolidation as some may exit due to pricing pressures [12] - There is a growing opportunity for domestic companies to expand into international markets, particularly in North America and Europe, where demand for TNF-α inhibitors is rising [13]

武汉禾元生物科技股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中信建投证券股份有限公司 （一）股票简称：禾元生物 （二）扩位简称：武汉禾元生物 （三）股票代码：688765 （四）首次公开发行后总股本：357,500,000 股 二、风险提示 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，禾元生物尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初 期的投资风险，提醒投资者充分了解交易风险、理性参与新股交易，具体如下： 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海 ...

截至本公告披露日，BAT1806（托珠单抗）已获得中国国家药品监督管理局 （NMPA）、美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）的上 市批准，中国商品名为施瑞立®，美国商品名为 TOFIDENCE ®。 协议履行的风险详见公司于 2025 年 8 月 21 日披露的《百奥泰生物制药股份 有限公司关于与 STADA 就 BAT1806（托珠单抗）注射液签署授权许可与商业化 协议的公告》（公告编号：2025-058）之"五、协议履行的风险分析"。 敬请广大投资者注意投资风险，公司将严格按照有关规定及时对本协议后续 进展情况履行信息披露义务。 证券代码：688177 证券简称：百奥泰 公告编号：2025-067 百奥泰生物制药股份有限公司 自愿披露关于与 STADA 就 BAT1806（托珠单抗） 注射液签署授权许可与商业化协议收到首付款 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于北京时间 2025 年 8 月 20 日与 STADA ...

2025年10月17日，科创板将迎来一只受市场关注的医药创新股——必贝特（787759）。在"生物+小核酸/RNAi技术"备受资金追捧的背景下，这家公司被认 为是医药赛道中一个"潜力试金石"。但创新药本身就充满不确定性：高投入、长周期、审批风险，各类变量都能打乱预期。本文从业务定位、行业趋势、 可比对标、中签策略、风险警示、首日预测等维度，帮助你在打新决策中更加沉着冷静。 一、申购框架 & 公司基本面速览 • 发行/申购安排 必贝特本次拟公开发行9,000万股，占发行后总股本约20%。网上发行数量为1,440万股（约16%），申购代码为787759，发行价定为¥17.78元/股。 单户网上申购上限为14,000股（对应市值约14.0万元），顶格申购需持有沪市市值约14万元。 2024年归属于母公司股东的净亏损约¥5,599.83万元；2023年亏损更大。 公司资产负债率相对温和，杠杆压力相对可控。 观点总结：作为典型的创新药公司，盈利尚不可期，关键在于未来研发能否落地与商业化路径是否顺畅。 • 主业定位 & 技术路径 公司聚焦肿瘤、自身免疫病、代谢性疾病等领域的小核酸/siRNA平台+化学药布局。 其公开资料 ...

Core Viewpoint - The company He Yuan Bio is set to launch an IPO on the Sci-Tech Innovation Board with a total market value of 7.789 billion yuan and an issue price of 29.06 yuan per share [2]. Group 1: Company Overview - He Yuan Bio utilizes a rice endosperm cell bioreactor technology platform (OryzPur) for efficient recombinant protein production [2]. - The company is a pioneer in China in using rice endosperm cell bioreactors for drug production [2]. - The main business composition includes 80.64% from recombinant human albumin (pharmaceutical excipients, research reagents) and 19.36% from other sources [2]. Group 2: Financial Performance - The company reported a net profit of 25.22 million yuan in the last three years, with a projected increase of 3.92% in 2024 [3]. - Revenue for 2023 reached 24.26 million yuan, marking an 81.08% increase compared to the previous year [3]. - The net profit for 2022 was 13.40 million yuan, reflecting a decrease of 47.49% from 2021 [3]. Group 3: Fundraising Purpose - The funds raised will be directed towards the construction of a recombinant human albumin industrialization base and new drug research and development projects [3].

Core Viewpoint - The company is an innovative biopharmaceutical enterprise with a leading global plant bioreactor technology platform, focusing on the development of recombinant protein drugs and addressing clinical needs through its core product HY1001, which has shown promising results in clinical trials [5]. Company Overview - The company specializes in the biopharmaceutical industry, particularly in the production of recombinant proteins using rice endosperm cell bioreactors [5]. - The core product, HY1001, has completed Phase III clinical trials in China, demonstrating good safety and efficacy [5]. Financial Data - Revenue projections show an increase from 0.13 billion yuan in 2022 to 0.24 billion yuan in 2023, and slightly to 0.25 billion yuan in 2024 [6]. - Net profit is expected to worsen from -1.44 billion yuan in 2022 to -1.87 billion yuan in 2023, before improving to -1.51 billion yuan in 2024 [6]. - The cash flow from operating activities per share is projected to decline from -0.25 yuan in 2022 to -0.46 yuan in 2023, with an expected recovery to -0.20 yuan in 2024 [6]. Industry Context - The company operates within the pharmaceutical manufacturing sector, with a current market price-to-book ratio of 3.43 times, compared to the industry average of 32.08 times [2]. - The comparable companies in the sector, such as ShenZhou Cell and BaiAoTai, have experienced declines in stock prices of -9.02% and -11.87% respectively over the past month [3]. SWOT Analysis - **Strengths**: The company benefits from a unique plant bioreactor technology that allows for high-quality and safe recombinant protein production, with the potential for large-scale manufacturing [11]. - **Opportunities**: The biopharmaceutical sector is expected to grow due to increasing clinical demands, improved payment capabilities, and supportive government policies [12]. - **Weaknesses**: The company faces challenges in validating the commercialization of its core technologies and products, as well as navigating the regulatory approval processes for its plant-based drugs [12].

Summary of New Stock Offerings from October 13 to October 17 Core Viewpoint A total of five new stocks will be available for subscription in the upcoming week, covering industries such as home furnishings, pharmaceutical manufacturing, and computer communication equipment. Notable companies include Marco Polo, a leader in the domestic ceramic tile industry, and Heyuan Bio, a pioneer in the large-scale production of pharmaceutical proteins using rice embryo cell bioreactors. Group 1: Marco Polo - Marco Polo is the leading company in the domestic ceramic tile industry, with its "Marco Polo Tile" brand value ranking first in the industry for over a decade [2] - The company has a total market value of 14.79 billion, with an issuance price-to-earnings ratio of 14.27, significantly lower than the industry average of 32.2 [2] Group 2: Heyuan Bio - Heyuan Bio is recognized as the first in China to utilize rice embryo cell bioreactors for the large-scale production of pharmaceutical proteins, referred to as "rice hematopoiesis" [3] - The company is set to have its human albumin injection HY1001 approved by July 2025 [3] Group 3: Super Electronics - Super Electronics is a major global supplier of automotive electronic PCBs, covering the demand for PCBs across various parts of vehicles [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 4: Xi'an Yicai - Xi'an Yicai has developed into the largest producer and seller of 12-inch silicon wafers in mainland China, ranking sixth globally [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 5: Bibet - Bibet focuses on the independent research and development of innovative drugs, targeting major diseases such as tumors, autoimmune diseases, and metabolic diseases [4] - The company operates in the pharmaceutical manufacturing industry [4]

Core Insights - Eli Lilly (LLY.US) has initiated the first Phase III clinical trial (FRAmework-01) for its FRαADC drug LY4170156, which is developed by Mablink Bioscience, a company acquired by Eli Lilly [1] - LY4170156 utilizes a payload of the topoisomerase I inhibitor irinotecan, with a drug-to-antibody ratio (DAR) of 8 [1] - According to NextPharma database, there are currently 27 FRαADC drugs in development globally, with 11 in clinical stages [1] - Apart from the already marketed drug somatuzumab, LY4170156, Rinatabart sesutecan (Genmab), and BAT8006 (Baiyoutai) are the three fastest progressing drugs, all having initiated Phase III clinical trials [1]

Core Insights - 百奥泰与Intas Pharmaceuticals达成合作，Intas将独占BAT2506在加拿大市场的商业化权益 [1][2] - BAT2506是基于戈利木单抗开发的生物类似药，已获得中国NMPA、美国FDA和欧洲EMA的上市许可申请受理 [1][2] Company Overview - 百奥泰是一家位于中国广州的全球性生物制药企业，专注于开发新一代创新药和生物类似药，涵盖肿瘤、自身免疫性疾病等多个领域 [3] - 公司已推动多款药物获批上市，包括贝塔宁、阿达木单抗、托珠单抗等，且在抗体药物开发方面处于全球领先地位 [3] Strategic Importance - Accord BioPharma的高管表示，此次独家商业化协议将丰富其生物类似药产品管线，并对北美市场的业务增长具有重要战略意义 [2] - Accord致力于提升加拿大患者对生物类似药的可及性，并通过与百奥泰的合作推动生物类似药的引入 [2] Product Development - BAT2506是针对TNF-α的抗体，能够阻断TNF-α与其受体的结合，从而抑制其活性 [1][2] - 百奥泰在生物类似药的研发中遵循中国、美国和欧洲的相关指导原则，确保产品的高质量和安全性 [1][2]